A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

Completed · Phase 2

Conditions studied: Hodgkin Disease

In brief

The purpose of this study is to determine whether nivolumab plus brentuximab vedotin (followed by brentuximab vedotin plus bendamustine in patient with suboptimal response) is safe and effective in treating patients with Hodgkin's lymphoma (cHL). Eligible patients are children, adolescents, and young adults relapsed or refractory to first line.

Key facts

Study ID

NCT02927769

Run by

Bristol-Myers Squibb

People needed

72

Starts

2017-03-28

Expected to finish

2024-05-28

Last updated by the study team

2025-02-10

Who can join

Age: 5 and older, up to 30. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Classic Hodgkin Lymphoma (cHL), relapsed or refractory
• Minimal limitation on activities of daily living as measured by Karnofsky ≥ 50 for participants > 16 years of age or Lansky ≥ 50 for participants ≤ 16 years of age.
• One prior anti-cancer therapy that did not work

You may not qualify if…

• Active, known, or suspected autoimmune disease or infection
• Active cerebral/meningeal disease related to the underlying malignancy
• More than one line of anti-cancer therapy or no treatment at all
• Received a stem cell transplant for Hodgkin Lymphoma and/or a solid organ transplant
• Prior treatment with any drug that targets T cell co-stimulation pathways (such as checkpoint inhibitors)
• Other protocol defined inclusion/exclusion criteria apply

Where it is running

• Phoenix Children'S Hospital — Phoenix, Arizona, United States
• Loma Linda University Cancer Center — Loma Linda, California, United States
• Valley Children's Hospital — Madera, California, United States
• Children'S Hospital & Research Center At Oakland — Oakland, California, United States
• Children'S Hospital Of Orange County — Orange, California, United States
• Lucile Packard Children'S Research Hospital/Stanford Univ — Palo Alto, California, United States
• Local Institution - 0091 — San Diego, California, United States
• Childrens Hospital of Colorado — Aurora, Colorado, United States
• Smilow Cancer Hospital At Yale New Haven Hospital — New Haven, Connecticut, United States
• Nemours / A. I. duPont Hospital for Children — Wilmington, Delaware, United States
• Children'S National Medical Center — Washington D.C., District of Columbia, United States
• Local Institution - 0062 — Jacksonville, Florida, United States
• Local Institution - 0069 — St. Petersburg, Florida, United States
• Children's Healthcare Of Atlanta — Atlanta, Georgia, United States
• University Of Iowa — Iowa City, Iowa, United States
• Local Institution - 0070 — Baltimore, Maryland, United States
• Dana Farber Cancer Institute. — Boston, Massachusetts, United States
• Local Institution - 0097 — Detroit, Michigan, United States
• Local Institution - 0049 — Jackson, Mississippi, United States
• Local Institution - 0085 — Kansas City, Missouri, United States
• Washington University School Of Medicine — St Louis, Missouri, United States
• Nevada Cancer Research Foundation — Las Vegas, Nevada, United States
• Local Institution - 0067 — Hackensack, New Jersey, United States
• Local Institution - 0047 — New Brunswick, New Jersey, United States
• Children's Hospital of Alabama — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.